Effectiveness of the Botulinum Toxin for Treating Sialorrhea in Patients with Parkinson’s Disease: A Systematic Review
Open Access
- 6 March 2019
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (3) , 317
Abstract
The main objective was to assess the efficacy of botulinum toxin-based treatment for sialorrhea in adult patients with Parkinson’s disease. The search was performed by using the Medline-PubMed, EMBASE and Cochrane Library databases from January 2000–December 2017, in English/Spanish in patients with Parkinson’s disease and sialorrhea. The methodological quality of trials was carried out by following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria and the Newcastle–Ottawa Scale (NOS). Finally, a total of 21 articles were identified as fulfilling the inclusion criteria. There is no consensus regarding the site of injection of the toxin (single or multiple points), toxin dose or follow-up period. In all cases there was a reduction of sialorrhea. Treatment safety increases with the use of ultrasonography. Effects approximately occur at one week post-injection and for 3–5 months. Botulinum toxin is an effective therapeutic strategy or option in treating sialorrhea in adult patients with Parkinson’s disease. More studies with a better design, larger samples and a longer follow-up period are required to confirm these data.Keywords
This publication has 37 references indexed in Scilit:
- Sialorrhea: Anatomy, Pathophysiology and Treatment with Emphasis on the Role of Botulinum ToxinsToxins, 2013
- Volume matters: The influence of different botulinum toxin‐A dilutions for sialorrhea in amyotrophic lateral sclerosisMuscle & Nerve, 2012
- Ultrasound-guided botulinum toxin injections for treatment of droolingEuropean Annals of Otorhinolaryngology, Head and Neck Diseases, 2011
- Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: A prospective double‐blind trialMovement Disorders, 2011
- Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: Efficacy and possible mechanismsActa Odontologica Scandinavica, 2010
- BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SIALORRHEA IN PARKINSON'S DISEASEJournal of the American Geriatrics Society, 2008
- Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's diseaseMovement Disorders, 2007
- International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest studyMovement Disorders, 2006
- Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled studyMovement Disorders, 2006
- Double‐blind, placebo‐controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonismMovement Disorders, 2003